Additionally, EvolveImmune will receive option fees and milestone payments of up to $1.4bn, and tiered royalties on future ...

"AbbVie and EvolveImmune Therapeutics sign oncology collaboration" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article ...

Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...

This morning, pharma major AbbVie and fellow USA-based EvolveImmune Therapeutics announced the signing of a collaboration and ...

While Humira's sales volumes have increasingly shifted to other drugs over successive quarters this year, that has also ...

The biopharmaceutical company agreed to buy Aliada in a deal that adds a potential therapy for Alzheimer’s disease to ...

AbbVie announced Monday that it is buying Aliada Therapeutics for $1.4 billion.The deal includes Aliada’s lead drug candidate ALIA-1758, an experimental antibody being tested for treating ...

(Reuters) -AbbVie will buy Aliada Therapeutics for $1.4 billion in cash, it said on Monday, gaining access to the privately held therapy developer's Alzheimer's disease candidate as the U.S. drugmaker ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...